Telcagepant
Telcagepant (pronounced tel-KA-ge-pant) is a drug that was under development for the acute treatment of migraines. It belongs to the class of drugs known as calcitonin gene-related peptide receptor (CGRP receptor) antagonists.
Etymology
The name "Telcagepant" is derived from the drug's mechanism of action. "Tel" is a prefix meaning "end" or "complete," "cage" refers to the drug's ability to bind to the CGRP receptor, and "pant" is a suffix often used in pharmaceutical nomenclature to denote a drug that acts as an antagonist.
Pharmacology
Telcagepant works by blocking the CGRP receptor, which is involved in the transmission of pain signals in the brain. By blocking this receptor, Telcagepant can potentially stop a migraine attack in its tracks.
Clinical Trials
Telcagepant was studied in several clinical trials for its effectiveness in treating migraines. However, the drug was discontinued from development due to concerns about its potential to cause liver toxicity.
Related Terms
- Migraine: A neurological condition characterized by severe, debilitating headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound.
- Calcitonin gene-related peptide receptor (CGRP receptor): A receptor found in the brain that plays a key role in the transmission of pain signals.
- Clinical trial: A type of research study that tests how well new medical approaches work in people.
External links
- Medical encyclopedia article on Telcagepant
- Wikipedia's article - Telcagepant
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski